Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single center study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Statin treatment, oxidative stress and inflammation in a Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

OBJECTIVE: Given a proposed role for PD-L1+ and IL-10-producing B-cell subsets in promoting certain cancers, we sought to characterize the frequency and phenotype of B cells in patients with chronic myeloproliferative neoplasms (MPNs) and the influence of ruxolitinib and interferon-α2 therapy.

METHODS: We analyzed B-cell frequencies and phenotype in patients with MPNs (n=107), before and during treatment with ruxolitinib (n=29), interferon-α2 (n=21), or the two drugs in combination (COMBI) (n=42) and healthy donors (HDs) (n=52) using flow cytometry.

RESULTS: Myelofibrosis patients had lower lymphocyte counts and proportions of B cells than patients with essential thrombocytosis or polycythemia vera and HDs. The B-cell count correlated inversely with JAK2-V617F allele burden and spleen size and increased after ruxolitinib or COMBI treatment. The proportions of PD-L1+ B cells and PD-1+ B cells were significantly higher in patients with myelofibrosis or polycythemia vera than in HDs and decreased during ruxolitinib and COMBI treatment. The proportions of TNF-α+ and IL-6+ B cells were elevated in myelofibrosis patients. The proportion of IL-6+ B cells decreased, and the proportion of IL-10+ B cells increased during ruxolitinib treatment.

CONCLUSION: B-cell frequency and phenotype were altered in MPN patients. Ruxolitinib therapy had marked effects on both frequency and phenotype. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalEuropean Journal of Haematology
ISSN0902-4441
DOIs
Publication statusE-pub ahead of print - 11 Jul 2019

ID: 57728420